Haemocomplettan P

Haemocomplettan P is a human fibrinogen concentrate supplied as an intravenous solution for prescription use in the European Union. The product contains purified human fibrinogen, the protein that forms the structural basis of blood clots, and is administered by healthcare professionals to restore fibrinogen levels in patients with acquired or congenital deficiencies. It is classified as a hemostatic agent and is regulated as a prescription‑only medication.

Haemocomplettan P is indicated for the management of patients who have low fibrinogen concentrations that increase bleeding risk.

- Replacement therapy in congenital fibrinogen deficiency (afibrinogenemia, hypofibrinogenemia). - Treatment of acquired fibrinogen deficiency during massive hemorrhage, such as trauma or surgery. - Supportive care for bleeding associated with disseminated intravascular coagulation when fibrinogen levels are critically low. - Peri‑operative fibrinogen supplementation in cardiac or liver transplantation procedures. - Management of bleeding in obstetric hemorrhage when fibrinogen depletion is documented.

Adverse reactions reported with Haemocomplettan P are generally related to the infusion process or to the protein nature of the product. These events are monitored during and after administration.

Common: - Mild fever or chills during or shortly after infusion. - Headache or dizziness. - Nausea or vomiting. - Transient hypotension or mild hypertension. - Localized infusion site erythema or swelling. - Transient tachycardia or palpitations.

Serious: - Allergic or anaphylactic reactions, including urticaria, bronchospasm, or angioedema. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Severe hypotension or cardiovascular collapse. - Hemolysis or renal impairment secondary to immune complex formation. - Disseminated intravascular coagulation exacerbation.

When using Haemocomplettan P, clinicians should consider several precautionary measures to minimize risk and ensure appropriate patient selection.

- Verify fibrinogen level and clinical indication before initiating therapy. - Assess for a history of hypersensitivity to blood products or fibrinogen concentrates. - Monitor vital signs and coagulation parameters during and after infusion. - Use caution in patients with active thrombotic disease or a high risk of thrombosis. - Adjust dosing in individuals with renal or hepatic impairment as guided by laboratory values. - Avoid rapid infusion rates; follow recommended administration speed. - Document product lot number and traceability for pharmacovigilance.

Haemocomplettan P may interact with other agents that affect coagulation or immune response, requiring careful management.

Avoid: - Concomitant use of pro‑thrombotic agents (e.g., activated factor VII, prothrombin complex concentrates) without clear indication. - Simultaneous administration of other plasma‑derived fibrinogen products.

Use with caution: - Antifibrinolytic drugs such as tranexamic acid, which may increase clot stability. - Anticoagulants (heparin, direct oral anticoagulants) that could alter the balance between bleeding and thrombosis. - Immunosuppressive therapies that may mask allergic reactions. - High‑dose steroids, which could affect immune response to the protein.